<DOC>
	<DOCNO>NCT00687531</DOCNO>
	<brief_summary>Open label , 12-week clinical trial ass efficacy , safety , treatment adherence Quality Life impact Mometasone Furoate dry powder 400 mcg once-daily persistent mild-moderate asthmatic patient least 12 year old . Protocol deviation may occur result quality issue associate report data .</brief_summary>
	<brief_title>Clinical Trial Assess Efficacy , Safety , Treatment Adherence Quality Life Impact Mometasone Furoate Asthmatic Patients ( Study P04879 ) ( TERMINATED )</brief_title>
	<detailed_description />
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Willingness participate comply procedure sign write informed consent 12 year age old either gender race Women childbearing potential ( include woman less 1 year postmenopausal currently become sexually active study ) must use agree use acceptable method birth control unless surgically sterilize Must understand able adhere dose visit schedule , agree record symptom severity score , PEFR value , medication time , concomitant medication accurately consistently daily diary . Diagnosed history mildmoderate persistent asthma least 12 month . FEV1 must &gt; 60 % predict normal personal best FEV1 last 12 month . Using daily inhale corticosteroid least 30 day prior Screening . In Screening Visit patient FEV1 &gt; = 65 % &lt; = 90 % predict . Asthma Symptom Total daily ( AM+PM ) severity score Screening Visit &lt; = 2 . For two week prior Screening , subject must stable regimen one follow twice daily regimen : fluticasone propionate ( FP ) &gt; = 100 &lt; = 500 mcg/day ; budesonide ( BUD ) &gt; = 200 &lt; = 1000mcg/day ; beclomethasone dipropionate ( BDP ) &gt; = 200 &lt; = 1000 mcg/day ; triamcinolone acetonide ( TA ) &gt; = 400 &lt; = 2000 mcg/day During inhaled corticosteroid ( ICS ) Dose Reduction period ( max . 4 week ; min . 1 week ) sequential ICS Dose Reduction ( approximately 50 % reduction daily dose discontinue accord treatment scheme ) , subject must demonstrate measurable loss asthma control , A ) Decreased Lung Function ( Screening value absolute FEV1 &gt; = 10 % &gt; = 220ml OR decrease AM PEFR 25 % average value preICS Dose Reduction period least 2 consecutive day last 7 day ) AND B ) Increased Symptoms ( Total AM PM symptom score &gt; = 10 24 ( use 03 scale 4 individual symptom ) least 2 day last 7 day OR Increased use rescue medication average value preICS Dose Reduction period ( one week ) &gt; = 2 puff least 2 day last 7 day ) Once criterion fulfil , subject initiate FEV1 60 % 80 % predicted Subjects must agree inform usual treating physician participation study Females pregnant breastfeeding . Subjects observed designate washout period prohibit medication Subjects use investigational product within 30 day antibody asthma allergic rhinitis past 90 day prior enrollment . Subjects clinically significant deviation normal physical examination may interfere study evaluation affect subject safety . Subjects require systemic steroid within previous month . Subjects allergic idiosyncratic reaction corticosteroid . Subjects require inpatient hospitalization asthma control within previous 3 month , previous 6 month . Subjects clinical evidence chronic obstructive pulmonary disease lung diseases asthma . Subjects experience upper low respiratory tract infection within previous 2 week prior Screening Visit . Subjects evidence clinically significant oropharyngeal candidiasis Subjects clinically significant immunologic , metabolic , cardiovascular , neurologic , hematologic , gastrointestinal , cerebrovascular , respiratory disease ( asthma ) , disorder may interfere study evaluation affect subject safety . Subjects history drug abuse , antagonistic personality , poor motivation , hypochondriasis , emotional intellectual problem likely limit validity consent participate study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>